Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

Clinical Cancer Research, 04/06/2012

Addition of rituximab to MV is a novel therapeutic strategy for aggressive B–cell non–Hodgkin lymphoma (B–NHL) and warrants clinical trial evaluation.

Print Article Summary